Regentis Biomaterials Ltd. Ordinary Shares Overview
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Sector: Industrials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC® aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel im Read More
Newly listed company coverage
Verified company profile, price history, and SEC registration source are available.
10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.
Review the SEC registration filingReported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Recent News
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Annual 10-K/20-F financial statement data is not available yet.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.